Concurrent Investment Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.97M Buy
31,399
+2,026
+7% +$162K 0.02% 623
2025
Q4
$2.8M Buy
29,373
+14,235
+94% +$1.4M 0.03% 470
2025
Q3
$1.48M Buy
15,138
+54
+0.4% +$5.59K 0.03% 539
2025
Q2
$1.62M Buy
15,084
+1,839
+14% +$186K 0.03% 480
2025
Q1
$1.34M Buy
13,245
+3,509
+36% +$353K 0.03% 462
2024
Q4
$870K Buy
9,736
+12
+0.1% +$1.06K 0.02% 527
2024
Q3
$815K Buy
9,724
+530
+6% +$41.8K 0.02% 515
2024
Q2
$708K Buy
9,194
+893
+11% +$65.4K 0.02% 511
2024
Q1
$569K Buy
8,301
+1,066
+15% +$68.5K 0.02% 513
2023
Q4
$418K Buy
+7,235
New +$386K 0.02% 538

Other funds holding BSX

Concurrent Investment Advisors's BSX Position: Q1 2026 in Review

Concurrent Investment Advisors increased its Boston Scientific (BSX) stake by 6.9% in Q1 2026, buying an estimated $162K and bringing the position to 31,399 shares worth $1.97M. The position accounts for 0.02% of the portfolio, ranked #623.

Concurrent Investment Advisors first reported a position in BSX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.8M in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Concurrent Investment Advisors held 31,399 shares of Boston Scientific worth $1.97M as of Q1 2026.
  • Concurrent Investment Advisors bought 2,026 Boston Scientific shares in Q1 2026, an estimated $162K.
  • Boston Scientific made up 0.02% of Concurrent Investment Advisors's portfolio in Q1 2026, its #623 holding.
  • Concurrent Investment Advisors first reported a position in Boston Scientific in Q4 2023 and has held it in 10 quarters since.
  • Concurrent Investment Advisors's Boston Scientific position peaked at $2.8M in Q4 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.